New mRNA vaccine combo aims to prevent lung cancer recurrence in High-Risk patients
NCT ID NCT07513376
First seen Apr 23, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung cancer will be randomly assigned to receive the vaccine, the combination, or a placebo. The study aims to see if these treatments improve disease-free survival compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altru Health System ( Site 3254)
RECRUITINGGrand Forks, North Dakota, 58201, United States
Contact Phone: •••-•••-••••
-
Billings Clinic ( Site 3255)
RECRUITINGBillings, Montana, 59101, United States
Contact Phone: •••-•••-••••
-
Centre Hospitalier de l'Université de Montréal ( Site 2501)
RECRUITINGMontreal, Quebec, H2X 3E4, Canada
Contact Phone: •••-•••-••••
-
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506)
RECRUITINGHamilton, Ontario, L8V 5C2, Canada
Contact Phone: •••-•••-••••
-
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503)
RECRUITINGKingston, Ontario, K7L 2V7, Canada
Contact Phone: •••-•••-••••
-
NHO Revive Research Institute, LLC ( Site 3218)
RECRUITINGLincoln, Nebraska, 68506, United States
Contact Phone: •••-•••-••••
-
National Cheng Kung University Hospital ( Site 5300)
RECRUITINGTainan, 704, Taiwan
Contact Phone: •••-•••-••••
-
One Clinical Research ( Site 0501)
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-••••
-
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)
RECRUITINGReno, Nevada, 89502, United States
Contact Phone: •••-•••-••••
-
The University of Tennessee Medical Center ( Site 3223)
RECRUITINGKnoxville, Tennessee, 37920, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
intismeran (mRNA cancer vaccine) and pembrolizumab (immunotherapy)
What this could lead to
If successful, this could offer a new way to prevent early-stage lung cancer from coming back after surgery, potentially improving long-term survival.
What could go wrong
This is a large phase 3 trial, but the treatment is experimental. It may not work better than placebo, and side effects from immunotherapy or the vaccine could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.